Pembrolizumab Msi H Colon Cancer
Pembrolizumab Msi H Colon Cancer . This variant of the regimen is being listed despite lack of a published trial and results because this is the FDA-approved, recommended pembrolizumab dose and schedule in the package insert. View full prescribing information for KEYTRUDA. (PDF) Undifferentiated carcinoma of the transverse colon ... (Bobby Hudson) Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Pembrolizumab Addresses Unmet Need in MSI-H/dMMR Cancer Population. • MSI-H cancer represents a unique, biomarker-identified disease • Pembrolizumab addresses an unmet medical need with a favorable benefit risk profile in previously treated patients with advanced MSI-H cancer. Background Pembrolizumab (pembro) provides durable responses in patients (pts) with MSI-H cancers and is approved in the US/Japan for the treatment of MSI-H advanced solid tumors. In MSI-high colon cancer, the cells are ...